The Changing Face of Global Clinical Trials: Asia-Pacific as an Ideal Destination for Specialty Biopharma

CMIC: THE LARGEST JAPANESE INTEGRATED SERVICE PROVIDER PROVIDING FULL RANGE OF SERVICES

- Extensive presence in Japan, US, and Asia (33 bases in Japan, 12 overseas bases, 16 Asian affiliates)
- 1000 clinical research associates, 600 medical representatives, and 50 regulatory consultants
- Vast expertise in legal, IP, manufacturing, and commercialization

Excellent Regulatory Track Record
- Supported >80% of drug approvals in Japan
- Strong relationship with PMDA and Ministry of Health, Labour and Welfare (MHLW) and other regulatory bodies
- Deep understanding of cross-border pre-clinical bioanalysis in US and Europe (FDA+EMEA), Japan, and Asia-Pacific

Vast Therapeutic Area Expertise
- Focus on Oncology, Neurology, and Rare Diseases
- CMIC’s regenerative medicine group has executed 50 projects from >20 companies since 2015

"Pharmaceutical Value Creator" model to support full-range services
- CRO: Supporting drug development
- CDMO: Supporting both drug development-stage and commercial-stage manufacturing
- CSO: Supporting pharmaceutical sales
- Healthcare: Supporting medical institutions (SMO) and elevating the health of individuals
- IPM: Innovative pharma model, including OrphanPacific, a dedicated subsidiary on rare diseases

Areas to Watch: Global Biologics and Orphan Drugs Market Revenue Growth*
- USD375 billion forecast market for Biologics drugs by 2022
- USD220 billion forecast market for Orphan drugs by 2022
- 20% of orphan drugs expected to capture prescription drug sales by 2020.
- 50% of the top 20 Orphan pipeline drugs will be from mid to small biotech companies based on net present value in 2015

Clinical Trials Outsourcing: Key Drivers for small and mid-sized companies in the US
- Lengthy trial time due to differences in US Federal, State and Institutional policies
- Rising cost of drug discovery & development, and lack of extensive in-house R&D talent and infrastructure
- Long and challenging recruitment of desired patients due to high penetration of clinical trials in the US
- Laborious task to hire most sought-after investigators for small and mid-size pharmaceutical companies

Asia-Pacific is fast becoming the preferred destination for clinical trials

2016 USD4.89 B 2017 USD5.23 B 2018 USD6.46 B
2016 USD30.5 B 2017 USD39.5 B 2018 USD52.3 B
2016 USD35.4 B 2017 USD40.5 B 2018 USD64.6 B

Asia-Pacific: AT 20.3% CAGR
Rest of the World: AT 11.6% CAGR
Global: AT 12.8% CAGR

Areas to Watch: Global Biologics and Orphan Drugs Market Revenue Growth*

Pharmaceutical Market Trends
- Slowdown expected in pharma industry growth rate to 4.2% (2016-2020) from 4.5% (2012-2015)
- Expansion to emerging countries for access to new markets
- Regulatory & pricing pressures
- Patent cliff of blockbusters and personalized medicine trend shifting R&D focus to orphan drugs and biologics

To learn more about Asia as a preferred destination for CRO, its advantages and how CMIC can support small and mid-sized pharmaceutical companies in their innovation journey, download the white paper here.

www.cmicgroup.com

5 KEY PARAMETERS TO SELECTING THE RIGHT CRO PARTNER

1. Global support and scalability
2. Significant presence in Asia with deep local market knowledge
3. Strong relationship with local regulators, investigators and KOLs
4. Exemplary regulatory track record
5. Therapeutic expertise aligned to specialty pharma

*Source: The Economic Intelligence Unit; BMI Research; Frost & Sullivan; Global Orphan Drug Market, Nov 2016